Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
by
Labrie, Bridget M.
, Ness, Dylan B.
, Tosteson, Tor D.
, Eastman, Alan
, Pooler, Darcy B.
, Lansigan, Frederick
, Danilov, Alexey V.
, Lewis, Lionel D.
in
Adverse events
/ Autopsy
/ Biomarkers
/ Blood platelets
/ Body mass index
/ Chronic lymphocytic leukemia
/ Clinical outcomes
/ Demography
/ Diarrhea
/ Enzyme inhibitors
/ Fever
/ Guano
/ Hematology
/ Informed consent
/ Leukemia
/ Leukocytes (neutrophilic)
/ Neutropenia
/ Patients
/ Platelets
/ Pneumonia
/ Remission
/ Remission (Medicine)
/ Thrombocytopenia
/ Toxicity
/ Vomiting
2022
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
by
Labrie, Bridget M.
, Ness, Dylan B.
, Tosteson, Tor D.
, Eastman, Alan
, Pooler, Darcy B.
, Lansigan, Frederick
, Danilov, Alexey V.
, Lewis, Lionel D.
in
Adverse events
/ Autopsy
/ Biomarkers
/ Blood platelets
/ Body mass index
/ Chronic lymphocytic leukemia
/ Clinical outcomes
/ Demography
/ Diarrhea
/ Enzyme inhibitors
/ Fever
/ Guano
/ Hematology
/ Informed consent
/ Leukemia
/ Leukocytes (neutrophilic)
/ Neutropenia
/ Patients
/ Platelets
/ Pneumonia
/ Remission
/ Remission (Medicine)
/ Thrombocytopenia
/ Toxicity
/ Vomiting
2022
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
by
Labrie, Bridget M.
, Ness, Dylan B.
, Tosteson, Tor D.
, Eastman, Alan
, Pooler, Darcy B.
, Lansigan, Frederick
, Danilov, Alexey V.
, Lewis, Lionel D.
in
Adverse events
/ Autopsy
/ Biomarkers
/ Blood platelets
/ Body mass index
/ Chronic lymphocytic leukemia
/ Clinical outcomes
/ Demography
/ Diarrhea
/ Enzyme inhibitors
/ Fever
/ Guano
/ Hematology
/ Informed consent
/ Leukemia
/ Leukocytes (neutrophilic)
/ Neutropenia
/ Patients
/ Platelets
/ Pneumonia
/ Remission
/ Remission (Medicine)
/ Thrombocytopenia
/ Toxicity
/ Vomiting
2022
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
Journal Article
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
2022
Request Book From Autostore
and Choose the Collection Method
Overview
Targeted therapies such as the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib are better tolerated and have become standard of care for CLL. TABLE 1 Patient demographics and outcomes Patient demographic All cohorts n = 6 Cohort 1 (8 mg/m2) n = 3 Cohort 2 (12 mg/m2) n = 3 a Sex Male 5 2 3 Female 1 1 0 Age Median (range) 72 (52–75) 71 (52–75) 73 (60–75) <65 y 2 1 1 ≥65 y 4 2 2 BMI Median (range) 31.0 (21.2–38.2) 26.5 (21.2–32.9) 32.1 (29.9–38.2) Race White 6 (100%) 3 (100%) 3 (100%) Ethnicity Other (non-Hispanic/Latino) 6 (100%) 3 (100%) 3 (100%) ECOG score 0 1 (16.7%) 1 (33.3%) 0 (0%) 1 5 (83.3%) 2 (66.7%) 3 (100%) Years since diagnosis Median (range) 9.5 (8–12) 9 (8–12) 10 (9–10) Prior therapies Median (range) 2.5 (1–8) 2 (1–8) 3 (2–3) Prior ibrutinib 2 1 1 Patient outcomes # Cycles completed Median (range) 4.9 (1.7–6) 4.5 (2–5.3) 6 (1.7–6) # Days on study Median (range) 128 (49–178) 104 (100–154) 152 (49–178) Adverse events Median (range) 6 (2–12) 6 (6–12) 8 (2–12) Serious adverse events Total 2 1 b 1 a, c Dose limiting toxicity Total 1 0 1 Best response achieved d PR 1 a 0 1 SD 3 2 1 NE 2 1 1 a One patient initially received BNC105P 12 mg/m2 monotherapy in cycle 1 and ibrutinib 420 mg monotherapy in cycle 2 (days 1–7) but because of a 25%–50% drop in platelets from baseline (from Gr1 →Gr2) was dose reduced to 8 mg/m2 BNC105P and ibrutinib 280 mg daily (as proscribed in the protocol but not a defining DLT) and subsequently tolerated this dose for six cycles with a partial remission. b This SAE was a patient who developed cryptococcal pneumonia following heavy self-exposure to bat droppings (guano) while cleaning an attic. The SAE occurred on study cycle 3 day 7, which was outside the defined DLT time window for the study. c This SAE was sudden death (of unknown cause; no autopsy) of the patient described in footnote a who completed six cycles of 8 mg/m2 BNC105P + Ibrutinib 280 mg daily and was off combination study treatment and being treated only with ibrutinib monotherapy when the SAE occurred. d BMI, body mass index; ECOG, Eastern Cooperative Group; NE, not evaluable; PR, partial remission; SD, stable disease. Two SAEs occurred: one sudden death (unknown cause) occurred 10 days after completing study combination treatment while receiving ibrutinib monotherapy; one patient in cohort 1 developed cryptococcal pneumonia on C3D7 following heavy exposure to bat droppings (guano) at a timepoint beyond the defined DLT time window.
This website uses cookies to ensure you get the best experience on our website.